Prospective, multicenter diagnostic accuracy study of a noninvasive blood-based test (ENDOmark) for suspected endometriosis. Included 652 premenopausal women undergoing laparoscopy for pelvic pain, infertility, or suspected endometriosis. All participants had preoperative pelvic imaging (ultrasound and/or MRI) and the blood test, then surgical and histology confirmation as reference standard. Primary outcomes were sensitivity, specificity, and diagnostic performance overall and in women with negative or inconclusive imaging.
Among 652 women, 348 (53%) had endometriosis confirmed at surgery. Overall test sensitivity was about 88% and specificity about 91%, with an area under the curve (AUC) around 0.94, indicating high accuracy. In women whose imaging was negative or inconclusive, the test still detected a large portion of cases—correctly identifying most with early-stage, ovarian, and deep infiltrating disease. The test outperformed imaging alone in this population and meaningfully reduced the number of missed cases.
Participants were all already scheduled for laparoscopy, so they may not represent the broader population with milder or less specific symptoms; test performance in primary care or general fertility clinics may differ. The study was conducted in specialized centers, likely with expertise in imaging and surgery, which may not reflect real-world variability. Potential conflicts of interest or industry involvement in developing and validating the test are likely, and independent replication is essential. The test cannot localize lesions, grade disease, or replace surgical assessment where needed, and it should not be used as the sole basis for major treatment decisions.
The study suggests that a validated blood-based biomarker panel can substantially improve noninvasive detection of endometriosis, especially in patients whose imaging appears normal. Methodology is relatively strong for a diagnostic study: prospective design, surgical/histologic reference standard, and a sizable, symptomatic cohort. However, results come from a selected population already heading to laparoscopy, which may inflate performance compared to a general gynecology or primary-care setting. This aligns with the broader literature seeking noninvasive markers for endometriosis but stands out by demonstrating higher accuracy than many earlier biomarker attempts; replication by independent groups and in more diverse populations is still needed.
Normal ultrasound or MRI does not reliably rule out endometriosis, especially in women with ongoing pain or fertility issues. A blood-based test like ENDOmark, if validated and available locally, may help support earlier suspicion of endometriosis and justify more complete evaluation instead of watchful waiting. Within a restorative framework, such a test could be combined with cycle charting, hormone profiling, and inflammatory/metabolic assessment to build a fuller picture of root causes. Patients can use this evidence to advocate for further evaluation when symptoms persist despite reassuring imaging.
This study looked at a new blood test designed to help detect endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus and can cause pain and fertility problems. Many women in the study had normal or unclear ultrasound or MRI, but still had endometriosis found at surgery; the blood test correctly picked up many of these hidden cases. For someone on a fertility or healing journey, this supports the idea that normal imaging does not always mean “nothing is wrong,” and that deeper evaluation can be appropriate when symptoms continue. In a root-cause approach, this kind of test would be one piece of the puzzle alongside careful symptom history, cycle charting, hormone and inflammation checks, and gentle, restorative treatment planning.
Consider noninvasive biomarker panels like ENDOmark as adjuncts when imaging is negative or equivocal but clinical suspicion remains high (cyclic pain, dyspareunia, dyschezia, subfertility). The test showed good performance across rASRM I–IV and for DIE/ovarian disease, which may support earlier diagnosis and targeted referral to advanced laparoscopic centers. Integration with restorative protocols: pair with detailed cycle charting (e.g., cervical mucus patterns, luteal phase parameters), endocrine workup (E2, P4 dynamics, LH, AMH, thyroid), inflammatory/metabolic markers (hs-CRP, insulin resistance, vitamin D), and immune evaluation where indicated. Use results to justify careful shared decision-making about timing of laparoscopy, medical suppression, and multimodal pain/inflammation management rather than as a stand-alone gatekeeper; remain cautious about overreliance until independent external validation and cost-effectiveness data are available.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.